RxDoctor Payments Data

Cynthia Herrick, MD

Endocrinology, Diabetes & Metabolism · Saint Louis, MONPI 1316074743

Payments from drug & device makers

$522in general payments, 2019–2025

Across 8 payments — averaging $65.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • BETA Bionics, Inc.$126
  • Novo Nordisk$126
  • Boehringer Ingelheim$125
  • Abbott$104
  • Lilly USA, LLC$26
  • AstraZeneca$16

What the payments were for

  • Food & beverage$522100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$522 in reported general payments places this provider in the 30th percentile of 182 endocrinology, diabetes & metabolism providers in Missouri.

See all endocrinology, diabetes & metabolism providers in Missouri

Medicare billing

Part B allowed, 2024
$174,850
Medicare patients
175
Services billed
9,591

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide71$99,714
MounjaroTirzepatide41$46,337
TrulicityDulaglutide36$45,261
JardianceEmpagliflozin45$45,241
Tresiba Flextouch U-200Insulin Degludec16$16,670
Tresiba Flextouch U-100Insulin Degludec14$10,752
Humalog Kwikpen U-100Insulin Lispro26$8,577
SynthroidLevothyroxine Sodium53$6,698
Lantus SolostarInsulin Glargine,hum.Rec.Anlog45$5,762
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog13$5,569
Insulin Lispro Kwikpen U-100Insulin Lispro21$4,535
Estradiol (Twice Weekly)Estradiol48$3,917
Nano 2nd Gen Pen NeedlePen Needle, Diabetic28$3,259
Estradiol Valerate13$2,427
LantusInsulin Glargine,hum.Rec.Anlog19$1,910

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$126$99,71471 claims
Lilly USA, LLCMounjaro, Trulicity$26$91,59877 claims
Boehringer IngelheimJardiance$125$45,24145 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 182 endocrinology, diabetes & metabolism providers in Missouri.

Other endocrinology, diabetes & metabolism in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →